Overview
Spherix’s coverage of the dynamic renal anemia market monitors and closely tracks the evolving landscape of anemia of CKD treatments, including iron (oral and IV), ESAs, and upcoming (and highly anticipated) new HIF-PH inhibitors. Quarterly tracking, monthly pulses on new launches, and deep dives into patient date position Spherix uniquely as experts in this market.
Services Available
Trending market evolution
Renal Anemia (US) - quarterly, n=200
Exploring the patient journey
Renal Anemia in CKD Non-Dialysis (US) - n=1,000 patient charts
Renal Anemia in Dialysis (US) - n=1,000 patient charts
Renal Anemia in Incident Dialysis (US) - n=1,000 patient charts
Benchmarking new brand performance
Roxadustat (FibroGen/AstraZeneca/Astellas) in Anemia*
Vadadustat (Akebia/Otsuka) in Anemia*
*Pending approvals and launch
Gauging impact of disruptive events
Multi-Specialty Impact of COVID-19 (US)
Reaction to Roxadustat Advisory Committee Meeting (US)